Komori
Shionogi & (4507) · InitiativeFirst stated

Acquisition of the rare neurological disease treatment business through the acquisition of IntraBio

First written in FY2027-H1. . Latest entry: FY2027-H1.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Acquisition of the rare neurological disease treatment business through the acquisition of IntraBioA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2027-H1First statedAnnual report

    「Through this transaction, Shionogi Inc. plans to acquire all issued shares of IntraBio and make it a wholly owned subsidiary. Through this transaction, the Company plans to acquire all worldwide rights, including intellectual property rights and commercialization rights, to AQNEURSA (generic name: levacetylleucine), which is approved to treat Niemann-Pick disease type C (NPC) and ataxia-telangiectasia (A-T), and to related compounds.」

    The Company disclosed that it entered into an acquisition agreement with IntraBio on 5 October 2026 and plans to acquire the worldwide rights to the approved drug AQNEURSA and other products for rare neurodegenerative and hereditary neurological diseases, as well as all shares of IntraBio.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Shionogi & yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Acquisition of the rare neurological disease treatment business through the acquisition of IntraBio | Shionogi & Co.,Ltd. (4507) | Komori